Giladi Moshe
SEC CIK 2001639 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | CSO | 69.8K | — | — | 1 | 2024-02-27 | 2024-02-27 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
Giladi Moshe made no open-market trades at NVCR in the last 12 months.
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-29 | 2024-02-27 | NVCR | NovoCure Ltd | Giladi Moshe | CSO | A - Grant | $16.30 | +51.1K | 69.8K | +274% | +$833.3K |
Purchase Sale Sale after option exercise All abbreviations